Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 compared with other fluoroquinolone-resistant E. coli

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4471-4480

  Johnson, James R ^a,b   Johnston, Brian ^a,b   Kuskowski, Michael A ^a,b   Sokurenko, Evgeni V ^c   Tchesnokova, Veronika ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ESCHERICHIA COLI INFECTION; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; PROCEDURES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84939824524     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00673-15     Document Type: Article

References (41)

1. Russo TA, Johnson JR. 2003. Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlooked epidemic. Microbes Infect 5:449-456. http://dx.doi.org/10.1016/S1286-4579(03)00049-2.
2. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1-14. http://dx.doi.org/10.1093/jac/dkq415.
3. Peirano G, Pitout JDD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35:316-321. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.003.
4. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51:286-294. http://dx.doi.org/10.1086/653932.
5. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddel K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine M, Debroy C, Robicsek A, Hansen G, Urban C, Platell JL, Trott DJ, Zhanel G, Weissman SJ, Cookson B, Fang F, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko E. 2013. Abrupt emergence of a single dominant multi-drug-resistant strain of Escherichia coli. J Infect Dis 207:919-928. http://dx.doi.org/10.1093/infdis/jis933.
6. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx. mBio 4(6):e00377-13. http://dx.doi.org/10.1128/mBio.00377-13.
7. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002-2004. Antimicrob Agents Chemother 53:2733-2739. http://dx.doi.org/10.1128/AAC.00297-09.
8. Nicolas-Chanoine M, Bertrand X, Madec J-Y. 2014. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27:543-574. http://dx.doi.org/10.1128/CMR.00125-13.
9. Petty NK, Ben Zakour N, Stanton-Cook M, Skippington E, Totsika M, Forde B, Phan M-D, Moriela DG, Peters K, Davies M, Rogers BA, Dougand G, Rodriguez-Baño J, Pascual A, Pitout J, Upton M, Paterson DL, Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:5694-5699. http://dx.doi.org/10.1073/pnas.1322678111.
10. Peirano G, van der Bij AK, Freeman JL, Poirel L, Nordmann P, Costello M, Tchesnokova VL, Pitout JDD. 2014. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 58:3762-3767. http://dx.doi.org/10.1128/AAC.02428-14.
11. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans. Clin Infect Dis 57: 1256-1265. http://dx.doi.org/10.1093/cid/cit503.
12. Croxall G, Hale J, Weston V, Manning G, Cheetham P, Achtman M, McNally A. 2011. Molecular epidemiology of extraintestinal pathogenic Escherichia coli isolates from a regional cohort of elderly patients high-lights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. J Antimicrob Chemother 66:2501-2508. http://dx.doi.org/10.1093/jac/dkr349.
13. Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW. 2013. Clonal composition and community clustering of drug-susceptible and resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 57:490-497. http://dx.doi.org/10.1128/AAC.01025-12.
14. Riley LW. 2014. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect 20:380-390. http://dx.doi.org/10.1111/1469-0691.12646.
15. Vimont S, Boyd A, Bleibtreu A, Bens M, Goujon J-M, Garry L, Clermont O, Denamur E, Arlet G, Vandewalle A. 2012. The CTX-M-15-producing Escherichia coli clone O25b:H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 7:e46547. http://dx.doi.org/10.1371/journal.pone.0046547.
16. Sorlozano A, Gutierrez J, Jimenez A, de Dios Luna J, Martínez JL. 2007. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. J Clin Microbiol 45:2740-2742. http://dx.doi.org/10.1128/JCM.01093-07.
17. Hopkins KL, Davis RH, Threlfall EJ. 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 25:358-373. http://dx.doi.org/10.1016/j.ijantimicag.2005.02.006.
18. Komp Lindgren P, Karlsson A, Hughes D. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 47: 3222-3232. http://dx.doi.org/10.1128/AAC.47.10.3222-3232.2003.
19. Paltansing S, Kraakman MEM, Ras JMC, Wessels E, Bernards AT. 2013. Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a Dutch teaching hospital reveals the presence of an Escherichia coli ST131 clone with a specific mutation in parE. J Antimicrob Agents 68:40-45. http://dx.doi.org/10.1093/jac/dks365.
20. Nam YS, Cho SY, Yang HY, Park KS, Jang JH, Kim YT, Jeong JW, Suh JT, Lee HJ. 2013. Investigation of mutation distribution in DNA gyrase and topoisomerase IV genes in ciprofloxacin-non-susceptible Enterobacteriaceae isolated from blood cultures in a tertiary care university hospital in South Korea, 2005-2010. Int J Antimicrob Agents 41:126-129. http://dx.doi.org/10.1016/j.ijantimicag.2012.10.004.
21. Bansal S, Tandon V. 2011. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates. Int J Antimicrob Agents 37:253-255. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.022.
22. Moon DC, Selo SY, Gurun M, Jin JS, Choi CH, Kim J, Lee YC, Cho DT, Lee JC. 2010. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates. Int J Antimicrob Agents 35:76-79. http://dx.doi.org/10.1016/j.ijantimicag.2009.08.003.
23. Park CH, Robicsek A, Jacoby GA, Sahm DF, Hooper DC. 2006. Prevalence in the United States of aac(6′)-1b-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 50:3953-3955. http://dx.doi.org/10.1128/AAC.00915-06.
24. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88. http://dx.doi.org/10.1038/nm1347.
25. Lautenbach E, Metlay JP, Mao X, Han X, Fishman NO, Bilker WB, Tolomao P, Wheeler M, Nachamkin I. 2010. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis 51:280-285. http://dx.doi.org/10.1086/653931.
26. Levy SB. 2002. Active efflux, a common mechanism for biocide and antibiotic resistance. J Appl Microbiol 92(Suppl):65S-71S. http://dx.doi.org/10.1046/j.1365-2672.92.5s1.4.x.
27. Weissman SJ, Johnson J, Tchesnokova V, Billig M, Dykhuizen D, Scholes D, Riddel K, Rogers P, Qin X, Fang F, Cookson B, Chattopadhyay S, Sokurenko E. 2012. High-resolution two-locus clonal typing of extraintestinal Escherichia coli. Appl Environ Microbiol 78:1353-1360. http://dx.doi.org/10.1128/AEM.06663-11.
28. Banerjee R, Robicsek A, Kuskowski M, Porter S, Johnston B, Sokurenko E, Tchesnokova V, Price L, Johnson JR. 2013. Molecular epidemiology of Escherichia coli sequence type ST131 and itsH30 andH30-Rx subclones among extended-spectrum beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago region (2007-2010). Antimicrob Agents Chemother 57:6385-6388. http://dx.doi.org/10.1128/AAC.01604-13.
29. Johnson JR, Nicolas-Chanoine M, Debroy C, Castanheira M, Robiscek A, Hansen G, Weissman SJ, Urban C, Platell JL, Trott DJ, Zhanel GG, Clabots C, Johnston BD, Kuskowski MA, MASTER Investigators. 2012. Comparison of Escherichia coli sequence type ST131 pulsotypes by epidemiologic traits, 1967-2009. Emerg Infect Dis 18:598-607. http://dx.doi.org/10.3201/eid1804.111627.
30. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MCJ, Ochman H, Achtman M. 2006. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 60:1136-1151. http://dx.doi.org/10.1111/j.1365-2958.2006.05172.x.
31. Tchesnokova V, Billig M, Chattopadhyay S, Linardopoulou E, Aprikian P, Roberts PL, Skrivankova V, Johnston B, Gileva A, Igusheva I, Toland A, Riddell K, Rogers P, Qin X, Butler-Wu S, Cookson BT, Fang FC, Kahl B, Price LB, Weissman SJ, Limaye A, Scholes D, Johnson JR, Sokurenko EV. 2013. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 51:2991-2999. http://dx.doi.org/10.1128/JCM.00984-13.
32. th ed. ASM Press, Washington, DC.
33. Asako H, Nakajima H, Kobayashi K, Kobayashi M, Aono R. 1997. Organic solvent tolerance and antibiotic resistance increased by overexpression of marA in Escherichia coli. Appl Environ Microbiol 63:1428-1433.
34. Oethinger M, Kern WV, Goldman JD, Levy SB. 1998. Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother 41:111-114. http://dx.doi.org/10.1093/jac/41.1.111.
35. White D, Goldman J, Demble B, Levy S. 1997. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol 179:6122-6126.
36. Campbell I. 2007. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 26:3661-3675. http://dx.doi.org/10.1002/sim.2832.
37. Vredenburg J, Varela AR, Hasan B, Bertilsson S, Olsen B, Narciso-da-Rocha C, Bonnedahl J, Stedt J, Da Costa PM, Manala CM. 2014. Quinolone-resistant Escherichia coli isolated from birds of prey in Portugal are genetically distinct from those isolated from water environments and gulls in Portugal, Spain and Sweden. Environ Microbiol 16:995-1004. http://dx.doi.org/10.1111/1462-2920.12231.
38. Liu X, Lazzaroni C, Aly SA, Thungrat K, Boothe DM. 2014. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates. Vet Microbiol 174:514-522. http://dx.doi.org/10.1016/j.vetmic.2014.10.011.
39. Yasufuku T, Shigemura K, Shirakawa T, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Nishimura K, Kawabata M, Fujisawa M. 2011. Risk factors and mechanisms of fluoroquinolone resistance in156 Escherichia coli strains clinically isolated from urinary tract infections. Scand J Infect Dis 43:83-88. http://dx.doi.org/10.3109/00365548.2010.526632.
40. Marcusson L, Frimodt-Moller N, Hughes D. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5:e1000541. http://dx.doi.org/10.1371/journal.ppat.1000541.
41. Peirano G, Pitout JDD. 2014. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother 58:2699-2703. http://dx.doi.org/10.1128/AAC.00119-14.